Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cabometyx
Pharma
FDA recognizes 'crossover impact' on survival in Cabometyx nod
The FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors after canceling a planned advisory committee meeting.
Angus Liu
Mar 26, 2025 11:03am
Exelixis shifts focus as triplet misses OS mark in kidney cancer
Feb 18, 2025 1:30pm
FDA cancels adcomm for Cabometyx in neuroendocrine tumors
Jan 10, 2025 9:46am
ICER calls out drugmakers over 'unsupported' price hikes
Dec 12, 2024 2:24pm
Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors
Nov 27, 2024 11:30am
Exelixis stock rises as Cabometyx withstands patent challenge
Oct 16, 2024 10:37am
